Summary
Vertex Pharmaceuticals Inc. reported a significant turnaround in its financial performance for the quarter ended March 31, 2012, compared to the same period in the prior year. The company transitioned from a net loss of $176.1 million in Q1 2011 to a net income of $91.6 million in Q1 2012. This dramatic improvement was driven by the successful commercial launch and sales of its key products, INCIVEK and KALYDECO, which generated substantial product revenues. Additionally, royalty revenues from collaboration partners contributed positively to the top line. Despite increased operating expenses, largely due to higher research and development, sales, general, and administrative costs associated with commercialization efforts, Vertex achieved profitability. The company's strong cash position, bolstered by product sales, provides a solid foundation for continued investment in its robust pipeline of drug candidates targeting serious diseases like Hepatitis C and Cystic Fibrosis. Investors should monitor the ongoing clinical development and potential regulatory approvals of these pipeline assets, as well as the competitive landscape for its existing products.
Financial Highlights
49 data points| Revenue | $438.74M |
| Cost of Revenue | $25.92M |
| Gross Profit | $412.82M |
| R&D Expenses | $196.37M |
| SG&A Expenses | $111.15M |
| Operating Expenses | $347.09M |
| Operating Income | $91.65M |
| Interest Expense | -$150K |
| Net Income | $91.59M |
| EPS (Basic) | $0.44 |
| EPS (Diluted) | $0.43 |
| Shares Outstanding (Basic) | 208.02M |
| Shares Outstanding (Diluted) | 219.26M |
Key Highlights
- 1Net income attributable to Vertex swung to $91.6 million in Q1 2012 from a net loss of $176.1 million in Q1 2011.
- 2Total revenues surged by 496% to $438.7 million in Q1 2012, primarily driven by the introduction of product revenues ($375.4 million) from INCIVEK and KALYDECO.
- 3Research and development expenses increased by 24% to $196.4 million, reflecting continued investment in the company's pipeline.
- 4Sales, general, and administrative expenses rose by 55% to $111.1 million, supporting the commercialization of INCIVEK and KALYDECO.
- 5The company ended the quarter with a strong liquidity position, holding $980.9 million in cash, cash equivalents, and marketable securities.
- 6Collaborative revenues decreased by 64% to $24.4 million, mainly due to the absence of significant milestone revenues recognized in the prior year's comparable quarter.